Clinical trials: SPECT-CT
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate
- Trial name
- ARROW (NCT03939689)
- Testing
- I-131-1095, Enzalutamide
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Cancer
Demonstration of the "SPECT/CT System With CZT Detectors" Imaging Performance in a Clinical Setting
The primary purpose of the study is to obtain sample clinical images that are evaluated by physicians in support of regulatory submissions.
- Trial name
- NCT03229772
- Testing
- Discovery NM/CT 670 CZT Imaging Scan
- Where
- Israel
- Volunteers
- 19 people
- Sponsor
- GE Healthcare